The phase III EPIK-B5 trial (NCT05038735) is currently studying the combination of alpelisib with fulvestrant or fulvestrant alone in patients with PIK3CA-mutated/HR+/HER2− BC who progressed under AI plus CDK4/6i. This evidence concerns the gene PIK3CA and breast cancer.